GlassScriptPhysician profile
James Collyer
NPI 1396907960
$114,878.98
in general payments reported to CMS, 2019-2025
23 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,924 · 2021: $1,389 · 2022: $1,521 · 2023: $9,149 · 2024: $34K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Consulting Fee: $12K · Food and Beverage: $7,976 · Travel and Lodging: $4,027 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,471.00 |
| Consulting Fee | $12,174.50 |
| Food and Beverage | $7,975.83 |
| Travel and Lodging | $4,026.91 |
| Education | $168.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $39,042.49 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $34,212.52 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $22,506.56 | 2019-2025 | |
| Leo Pharma INC. | $9,947.27 | 2022-2025 | Adbry, Anzupgo, Spevigo |
| E.R. Squibb & Sons, L.L.C. | $3,237.42 | 2022-2024 | Sotyktu, Camzyos |
| Abbvie INC. | $2,248.93 | 2019-2025 | Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $674.70 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $601.04 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $550.66 | 2023-2025 | Zoryve |
| Incyte Corporation | $378.43 | 2023-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $353.67 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $272.15 | 2019-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $177.16 | 2025 | Siliq, Cabtreo, Jublia |
| Allergan, INC. | $164.10 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $149.99 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $87.44 | 2023-2024 | Vtama |
| Revance Therapeutics, INC. | $80.83 | 2024-2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $55.49 | 2025 | |
| Pfizer INC. | $44.61 | 2022-2023 | |
| Lilly USA, LLC | $31.34 | 2025 | Ebglyss, Taltz |
| Vyne Pharmaceuticals INC. | $24.88 | 2020 | |
| Organon LLC | $24.81 | 2025 | Vtama |
| Amgen INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Collyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.